{"id":868689,"date":"2025-07-10T17:09:11","date_gmt":"2025-07-10T21:09:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/"},"modified":"2025-07-10T17:09:11","modified_gmt":"2025-07-10T21:09:11","slug":"investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/","title":{"rendered":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, July  10, 2025  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).<\/strong><\/p>\n<p>Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rCLvTIHablkYg0Q6DmC2oMGKjs43uHkPmtuIzz0kCIdgqfMabi-DvQxaqRwKLv01jDa5UUfFQNxftp0pIn931l30wq57QHez8sf4SCKpBIGYspDToPTM2hG5Ox3N_U26Vv2nrxPrG3WN4sY79PQFGjFKhRXQ3mtygXavj0xic_PgMsFCg35mX6wOg3pHwxrUsnUHJ-jd17bj1905_yd7vDT1iBLKiN5IiIXpngzQ-xp20KCDsPjnFY0AMTKMIY2rd0Iy7BGrQnjHgPjKp5QZ_uSrfk8CKNHHHhm7uuFNhSp-_UTRMAsPJ6PZVF_LoL_Oyhw1haoU71CVy_miLk7Q1Q==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/iovance-biotherapeutics-inc-loss-submission-form\/?id=156055&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>May 9, 2024 to May 8, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Iovance\u2019s growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers. On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) \u201cthe iCTC completed annual scheduled maintenance in December\u201d and \u201ccapacity was reduced by more than half for about 1 month,\u201d 2) \u201c[l]ower Proleukin sales\u201d than the company expected, and 3) \u201cthe variable pace at which ATCs began treatment patients.\u201d Following this news, the price of Iovance\u2019s common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance\u2019s stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day.<\/p>\n<p>\n        <strong>DEADLINE: July 14, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rCLvTIHablkYg0Q6DmC2oMGKjs43uHkPmtuIzz0kCIdgqfMabi-DvQxaqRwKLv01jDa5UUfFQNxftp0pIn931l30wq57QHez8sf4SCKpBIGYspDToPTM2hG5Ox3N_U26Vv2nrxPrG3WN4sY79PQFGuxlJJ3HL4S_hY4_dnejigeGOH9YWCfA-CQr3KMVMGLdh0Deg0vTyXLoZYPb0C3qT8QNOQ2fqTH73i7SvXlElBI3Pm4JvsUQR4mKobeGSrTL5DhXIJM9peY_wn3poFhht0uDnc4fxgWgED0LZI02WtHVGmkiCt_bgVDpSjfu8AlM1Vo7nqCHvmgd7jbSe-4ULw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/iovance-biotherapeutics-inc-loss-submission-form\/?id=156055&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of IOVA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 14, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zRjT4HnV7nk0jZAs7rPG5z3CcheIr7-rpHJdanxJA56oCvRFEGYDfBWDfwIQszVJ72gNQserne1MtjpY50Bo-b0kqaF0VL4jk16GV1Mx_74KhAhxJHbzURsogIu9x6pl\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2MxNjlhMmMtYjY5Ni00MzBjLTgxZjktN2M2ZDQwYTAyYmM5LTEyNzA0NjctMjAyNS0wNy0xMC1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/iovance-biotherapeutics-inc-loss-submission-form\/?id=156055&amp;from=3 CLASS PERIOD: May 9, 2024 to May 8, 2025 ALLEGATIONS: According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Iovance\u2019s growth potential; notably, that it was not equipped to generate and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868689","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/iovance-biotherapeutics-inc-loss-submission-form\/?id=156055&amp;from=3 CLASS PERIOD: May 9, 2024 to May 8, 2025 ALLEGATIONS: According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Iovance\u2019s growth potential; notably, that it was not equipped to generate and &hellip; Continue reading &quot;Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T21:09:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA\",\"datePublished\":\"2025-07-10T21:09:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/\"},\"wordCount\":492,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/\",\"name\":\"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\",\"datePublished\":\"2025-07-10T21:09:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/","og_locale":"en_US","og_type":"article","og_title":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk","og_description":"NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/iovance-biotherapeutics-inc-loss-submission-form\/?id=156055&amp;from=3 CLASS PERIOD: May 9, 2024 to May 8, 2025 ALLEGATIONS: According to the complaint, throughout the class period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Iovance\u2019s growth potential; notably, that it was not equipped to generate and &hellip; Continue reading \"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-10T21:09:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA","datePublished":"2025-07-10T21:09:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/"},"wordCount":492,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/","name":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=","datePublished":"2025-07-10T21:09:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2MSM3MDQwNTkyIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-iovance-biotherapeutics-inc-iova-should-contact-the-gross-law-firm-about-pending-class-action-iova\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action &#8211; IOVA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868689"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868689\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}